Annual report pursuant to Section 13 and 15(d)


12 Months Ended
Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Substantial Doubt about Going Concern [Text Block]



BioSig Technologies, Inc.’s primary efforts are principally devoted to improving the standard care in electrophysiology with our PURE EP System’s enhanced signal acquisition, digital signal processing, and analysis during ablation of cardiac arhythmias and ViralClear’s efforts are in developing additional applications of the PURE EP™ signal processing technology outside of cardiac electrophysiology. The Company has experienced net losses and negative cash flows from operations since inception and expects these conditions to continue for the foreseeable future. Further, the Company has not generated revenues and there is no assurance that the Company will be able to generate cash flow to fund operations. In addition, there can be no assurance that the Company's ongoing research and development will be successfully completed or that any product will be approved or commercially viable.


At December 31, 2020, the Company had working capital of approximately $24.2 million. During the year ended December 31, 2020, the Company raised approximately $25.2 million, net of expenses, through the sale of common stock, $10.6 million, net of expenses, through the sale of ViralClear’s common stock, $2.2 million through an At-the-market offering, net of expenses and $4.8 million from the exercise of warrants and options. In addition, the Company has in place a $45.0 million At-the-market offering, of which $42.5 million remains available at December 31, 2020 and on December 31, 2020, the Company filed a Form S-3, shelf registration statement for $75.0 million and subsequently on January 12, 2021 it was declared effective.


At December 31, 2020, the Company had cash of approximately $28.3 million, which together with approximately $1.3 million raised through filing, constitutes sufficient funds for the Company to meet its research and development and other funding requirements for at least the next 12 months from the date of issuance of these financial statements.